Citigroup Inc Century Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 34,087 shares of IPSC stock, worth $35,791. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,087

Previous 10,515 224.17%

Holding current value

$35,791

Previous $26,000 123.08%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.44 - $3.29 $33,943 - $77,551	23,572 Added 224.17%	34,087 $58,000
Q2 2024 Aug 12, 2024	BUY	$2.46 - $4.05 $14,560 - $23,971	5,919 Added 128.79%	10,515 $26,000
Q1 2024 May 10, 2024	BUY	$3.19 - $5.32 $3,438 - $5,734	1,078 Added 30.64%	4,596 $19,000
Q4 2023 Feb 09, 2024	BUY	$1.28 - $3.32 $3,537 - $9,176	2,764 Added 366.58%	3,518 $11,000
Q3 2023 Nov 09, 2023	SELL	$2.0 - $3.23 $15,170 - $24,499	-7,585 Reduced 90.96%	754 $1,000
Q2 2023 Aug 10, 2023	BUY	$2.91 - $3.53 $22,313 - $27,068	7,668 Added 1142.77%	8,339 $26,000
Q1 2023 May 11, 2023	SELL	$3.4 - $5.11 $734 - $1,103	-216 Reduced 24.35%	671 $2,000
Q4 2022 Feb 09, 2023	SELL	$4.84 - $11.58 $580 - $1,389	-120 Reduced 11.92%	887 $4,000
Q3 2022 Nov 10, 2022	SELL	$8.57 - $13.1 $9,984 - $15,261	-1,165 Reduced 53.64%	1,007 $10,000
Q2 2022 Aug 10, 2022	BUY	$7.96 - $12.43 $2,618 - $4,089	329 Added 17.85%	2,172 $18,000
Q1 2022 May 12, 2022	SELL	$11.62 - $15.92 $33,593 - $46,024	-2,891 Reduced 61.07%	1,843 $23,000
Q4 2021 Feb 10, 2022	BUY	$13.93 - $23.62 $47,348 - $80,284	3,399 Added 254.61%	4,734 $75,000
Q3 2021 Nov 10, 2021	BUY	$20.8 - $31.93 $27,768 - $42,626	1,335 New	1,335 $34,000

Others Institutions Holding IPSC

# of Institutions

Shares Held

36.9M

Call Options Held

8.7K

Put Options Held

10.2K

View Full List

About Century Therapeutics, Inc.

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $61.8M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

More about IPSC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account